Gabapentin
| 製品名 | Gabapentin |
|---|---|
| CAS番号 | 60142-96-3 |
| 分子式 | C9H17NO2 |
| 分子量 | 171.24 g/mol |
| 外観 | 白色からオフホワイトの結晶性粉末 |
| 分析(HPLC) | 98.0% – 102.0% |
| 乾燥減量 | ≤ 0.5% |
| 焼失残渣 | ≤ 0.1% |
| 重金属 | 10 ppm以下 |
| 溶解度 | Soluble in water, slightly soluble in ethanol |
| パッケージ | 25 kg fiber drum with double PE liner |
お困りですか? 弊社チームまでお問い合わせください

同義語: 1-(Aminomethyl)cyclohexaneacetic acid, Neurontin, Gabapentin, 2-[1-(Aminomethyl)cyclohexyl]acetic acid, CI-945, GOE-3450
Gabapentin has firmly established itself as a key API in the pharmaceutical industry, particularly for neurological and pain management therapies. Its unique mechanism of action and favorable safety profile have driven steady demand across both prescription and research sectors. As generic formulations expand and new therapeutic applications emerge, procurement teams are increasingly focused on securing reliable, high-purity gabapentin from qualified suppliers.
Gabapentin is a synthetic gamma-aminobutyric acid (GABA) analog, structurally distinct from endogenous GABA but capable of modulating neuronal excitability. It is synthesized through a multi-step chemical process, yielding a white to off-white crystalline powder that is freely soluble in water. The compound’s stability and bioavailability make it suitable for oral solid dosage forms, including tablets and capsules.
Commercial gabapentin is typically standardized to 98.0%–102.0% assay (HPLC), meeting pharmacopeial requirements such as USP and EP. Manufacturers and formulators value its consistent particle size distribution and low impurity profile, which facilitate robust tablet compression and uniform content uniformity. With patent expirations and growing generic competition, the focus has shifted to supply chain reliability, documentation transparency, and cost efficiency.
Gabapentin is a white to off-white crystalline powder with a molecular weight of 171.24 g/mol. It is chemically designated as 1-(aminomethyl)cyclohexaneacetic acid and is freely soluble in water, with slight solubility in ethanol. The compound is stable under normal storage conditions and is compatible with common excipients used in solid dosage forms.
Its structure incorporates a cyclohexane ring and an amino acid moiety, which contributes to its lipophilic character and ability to cross the blood-brain barrier. The active pharmaceutical ingredient (API) is typically produced via chemical synthesis, followed by purification steps to achieve high purity and consistent quality.
| パラメータ | 仕様 |
|---|---|
| 分析(HPLC) | 98.0% – 102.0% |
| 乾燥減量 | ≤ 0.5% |
| 重金属 | 10 ppm以下 |
| 焼失残渣 | ≤ 0.1% |
| Microbial Limits | Total aerobic count ≤ 1000 CFU/g |
| Impurities | Meets USP/EP requirements |